Ottawa announces MS clinical trials
Links shared publicly online about this topic.
- 182total visits
Ottawa announces MS clinical trials
View full resource at canada.com
Tags: Multiple Sclerosis, Clinical Trial
Most Recently Shared on June 30, 2011 at 12:25 am By:
Ottawa announces MS clinical trials http://t.co/K264XVF Why now and not last August? Decision not based on evidence.
American College of Surgeons Surgery News UPDATE
facs.org — “The American College of Surgeons is pleased to announce the launch of Surgery News UPDATE, a monthly e-newsletter created in partnership with Elsevier Global Medical News. As an offshoot of the official newspaper of the ACS, Surgery News UPDATE will further satisfy your need to be kept on top of emerging surgical trends, results of breaking clinical trials, and important developments in the various fields of surgery. Our professional medical journalists attend the meetings and review the literat” View full resource at facs.org
Most Recently Shared on January 13, 2012 at 8:40 pm By:
AmericanCollSurgeons Medical Society
Subscribe to Surgery News UPDATE, a monthly e-newsletter: http://t.co/AcMsD1nw #surgery #news #surgeons #newsletter
Sask. MS patients can apply for controversial clinical trial: premier - The Globe and Mail
theglobeandmail.com — “Premier Brad Wall announced Thursday the application process is open and residents can apply for one of 86 spots to participate in a clinical trial of a vein-widening procedure some say can alleviate symptoms of multiple sclerosis, a debilitating chronic disease” View full resource at theglobeandmail.com
Most Recently Shared on January 12, 2012 at 6:46 pm By:
David Steven Surgeon, Neurosurgeon, Physician, and Doctor
Sask. MS patients can apply for controversial clinical trial: premier http://t.co/1TXuhvPI via @globeandmail
Phase 3 Trial of Lemtrada for Multiple Sclerosis - MPR
empr.com — “Sanofi and Genzyme announced positive results from CARE-MS I, a randomized, Phase 3 clinical trial comparing Lemtrada (alemtuzumab) to Rebif (high dose subcutaneous interferon beta-1a; EMD Serono) in patients with relapsing-remitting multiple sclerosis (MS).” View full resource at empr.com
Most Recently Shared on October 24, 2011 at 5:30 pm By:
Phase 3 Trial of Lemtrada for Multiple Sclerosis http://t.co/1BkfHEYQ #multiplesclerosis
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial - Drugs.com MedNews
drugs.com — “240 mg of BG-12 Administered Either Twice or Three Times Oct 21, 2011 - Today Biogen Idec (NASDAQ BIIB) announced positive data from the Phase 3 DEFINE clinical” View full resource at drugs.com
Most Recently Shared on October 21, 2011 at 6:05 pm By:
Drugs and Devices OW OW Health
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progr... http://t.co/jn7sS4EA #drug
Researchers of controversial MS theory facing series of hurdles - The Globe and Mail
theglobeandmail.com — “Problems call into question timing of Ottawa’s decision to announce support for formal clinical trials of the vein-widening treatment in Canada” View full resource at theglobeandmail.com
Most Recently Shared on July 19, 2011 at 1:17 am By:
David Steven Surgeon, Neurosurgeon, Physician, and Doctor
Researchers of controversial MS theory facing series of hurdles http://t.co/9wa7dq0
Sanofi Reports Positive Top-Line Results From First Phase 3 Study Of Alemtuzumab (Lemtrada™) In Multiple Sclerosis
medicalnewstoday.com — “Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investi” View full resource at medicalnewstoday.com
Most Recently Shared on July 11, 2011 at 4:05 pm By:
Sanofi Reports Positive Top-Line Results From First Phase 3 Study Of Alemtuzumab (Lemtrada™) In Multiple Sclerosis http://mnt.to/3Y8K
Glycominds Announces Results for the Second Clinical Trial of Blood Test | IVD Technology
ivdtechnology.com — “Glycominds Ltd. (Modi’in, Israel) announced that the positive results of the gMSPro/CDMS (gMS-Classifier2) second clinical trial for predicting early conversion to clinically definite multiple sclerosis (CDMS) were presented at the Consortium for Multiple Sclerosis (CMSC) 2011 meeting. gMS-Classifier2 is based on the level of serum antibodies against the glucose molecule P63 and patient’s age.” View full resource at ivdtechnology.com
Most Recently Shared on June 6, 2011 at 7:04 pm By:
IVD Technology Health Magazine
Glycominds Announces Results for the Second Clinical Trial of Blood Test http://tinyurl.com/3scv6hd
Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference - Drugs.com MedNews
drugs.com — “May 3, 2011 - Aradigm Corporation (OTCBB ARDM) (the Company ) today announced that David Cipolla, M.S., Aradigm s Senior Director of Pharmaceutical Sciences, wi” View full resource at drugs.com
Most Recently Shared on May 5, 2011 at 6:12 pm By:
Drugs and Devices OW OW Health
Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conf... http://bit.ly/jgTUKt #drug
Stem cells: CIRM funds Geron Corp. spinal cord injury trial - latimes.com
latimes.com — “California's stem cell funding agency announced Wednesday that it will provide $25 million in funding for a clinical trial run by Geron Corp. The grant marks the first time CIRM has funded a human clinical trial.” View full resource at latimes.com
Most Recently Shared on May 4, 2011 at 10:19 pm By:
LA Times Health News Health News
Stem cells: CIRM funds Geron Corp. spinal cord injury trial http://lat.ms/knsCZ3
XenoPort Announces Plans for Phase 3 Development of Arbaclofen Placarbil for Spasticity | Business Wire
businesswire.com — “SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients. Following discussions with the U.S. Food and Drug Administration (FDA), XenoPort intends to conduct a single placebo-controlled Phase 3 efficacy clinical trial and an open-label, long-term, safety study of AP in patients with MS. Favorable resu” View full resource at businesswire.com
Most Recently Shared on September 13, 2010 at 1:28 pm By:
XenoPort Announces Plans for Phase 3 Development of Arbaclofen Placarbil for Spasticity: SANTA CLARA, Calif.--(BUS... http://bit.ly/d2amxy
CBC News - New Brunswick - N.L. to fund separate MS research
cbc.ca — “Newfoundland and Labrador's health minister made an impromptu announcement that his province will fund its own clinical trials into a controversial treatment for MS, speaking as national health ministers were meeting in St. John's.” View full resource at cbc.ca
Most Recently Shared on September 13, 2010 at 1:23 pm By:
Health ministers to weigh MS treatment issues: A controversial treatment for multiple sclerosis is expected to get... http://bit.ly/d3Rjv6
PhotoMedex Announces Clinical Trial Using The XTRAC Velocity(R) Laser In The Treatment Of Severe Generalized Psoriasis
medicalnewstoday.com — “PhotoMedex, Inc. (Nasdaq: PHMD) announced that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity® excimer laser in the treatment” View full resource at medicalnewstoday.com
Most Recently Shared on June 9, 2010 at 3:10 pm By:
MNT Dermatology News Dermatology and Health News
PhotoMedex Announces Clinical Trial Using The XTRAC Velocity(R) Laser In The Treatment Of Severe Generalized Psoriasis http://mnt.to/3DGW
Ipsen: Encouraging Preliminary New Data Available For The Treatment Of Short Stature Children With Low IGF-1 Levels
medicalnewstoday.com — “Ipsen (Paris:IPN), announced preliminary results from a Phase II open-label clinical trial (MS316 study) that evaluates the co-administration of recombinant human growth hormone (rhGH) and recombi” View full resource at medicalnewstoday.com
Most Recently Shared on September 17, 2009 at 12:57 pm By:
Ipsen: Encouraging Preliminary New Data Available For The Treatment Of Short Stature Children With Low IGF-1 Lev.. http://bit.ly/Cqfiv
Merck Seeks European License For Cladribine for relapsing remitting MS
medicalnewstoday.com — “Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes aft” View full resource at medicalnewstoday.com
Most Recently Shared on July 27, 2009 at 11:32 am By:
MedNewsToday: Merck Seeks European License For Cladribine for relapsing remitting MS: Merck Serono .. http://bit.ly/NUQkf
Advertisement
